Full-Time

Neurology Account Specialist

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Develops treatments for neurological disorders

Compensation Overview

$120.6k - $174.7k/yr

+ Incentive Compensation Plan

Senior, Expert

Company Does Not Provide H1B Sponsorship

Metter, GA, USA + 1 more

More locations: Jacksonville, FL, USA

Hybrid

Home office in Florida; role covers Southern Georgia as well.

Category
Field Sales
Sales & Account Management
Required Skills
SAP Products
QlikView
Salesforce
Oracle
Requirements
  • BS/BA degree in science or related field and 8+ years of commercial pharma/biotech or related experience, including 3+ years of specialty pharmaceutical sales experience, of which would include 2+ years of Neurology as applicable for the specialist role is highly desired.
  • Specialty pharmacy distribution experience is strongly preferred.
  • Psychiatry, neurology or antipsychotic experience strongly preferred.
  • Experience with business systems, salesforce automation platforms, and other business intelligence tools (e.g., Salesforce.com, Oracle database, SAP, Business Objects, COGNOS, QlikView, Veeva, etc.) OR Master's degree in science or related field and 6+ years of similar experience noted above.
Responsibilities
  • Creates product acceptance and manages sales and product growth through education opportunities in targeted Neurology accounts
  • Effectively executes sales force strategies and marketing plans to meet or exceed sales objectives through face-to-face or virtual communications via in-office visits, in-service presentations and speaker programs
  • Creates and implements successful strategies to further penetrate and segment the neurological movement disorder marketplace
  • Effectively uses promotional resources and budget
  • Establishes and maintains excellent communication and sound working relationships with co-workers and cross-functional partners, including managed care, Medical Science Liaisons, and medical communications
  • Demonstrates honesty and integrity while modeling behaviors consistent with company standards, values and corporate compliance policies
  • Identifies territory-specific opportunities and barriers to ensure product and company success
  • Develops local Opinion Leader relationships to achieve aligned objectives
  • Performs all responsibilities following the highest ethical standards, including FDA guidelines and best practices for the pharmaceutical/biotech industry
  • Effectively utilizes account selling strategies to achieve goals through building relationships with and meeting the needs of all members of the patients' care team (Pharm D, MD/NP/PA, LPN/RN)
  • Manages relationships with important customers, including key opinion leaders, local professional groups and advocacy groups, long-term care facilities, local and regional payers, and pharmacies
  • Other duties as assigned
Desired Qualifications
  • Specialty pharmacy distribution experience is strongly preferred.
  • Psychiatry, neurology or antipsychotic experience strongly preferred.
Neurocrine Biosciences

Neurocrine Biosciences

View

Neurocrine Biosciences develops treatments for neurological and endocrine-related diseases. Their main product, INGREZZA® (valbenazine), is used to treat tardive dyskinesia in adults. The company also has several other drug candidates in clinical development for conditions like Parkinson's disease and endometriosis. Unlike many competitors, Neurocrine focuses specifically on these areas, allowing them to build a specialized portfolio. Their goal is to improve the lives of patients suffering from these disorders through effective treatments.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA fast-track designation could expedite Neurocrine's drug approvals.
  • Growing mental health awareness expands market for Neurocrine's neuropsychiatric treatments.
  • Collaborations with academic institutions enhance Neurocrine's research and innovation access.

What critics are saying

  • Increased competition from Teva's generic Austedo affects INGREZZA's market share.
  • Patent litigation may delay NBI-1117568's commercialization for schizophrenia.
  • Strategic shifts from new CIO could disrupt Neurocrine's IT operations.

What makes Neurocrine Biosciences unique

  • Neurocrine focuses on neurological and endocrine disorders, a niche in biopharmaceuticals.
  • INGREZZA® is a leading treatment for tardive dyskinesia, setting Neurocrine apart.
  • Neurocrine's pipeline includes innovative drugs like NBI-1117568 for schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

Cache Valley Daily
Jun 9th, 2025
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

SAN DIEGO, June 9, 2025 /PRNewswire/ - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025.

GlobeNewswire
Jun 2nd, 2025
Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine...

PR Newswire
May 15th, 2025
Neurocrine Biosciences Presents Data On Improvements In Physiologic Glucocorticoid Dosing And Select Reproductive Hormones In Patients With Classic Congenital Adrenal Hyperplasia Taking Crenessity™ (Crinecerfont)

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction. Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions. Findings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult and pediatric patients achieved substantial reductions in glucocorticoid doses. These results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando

PR Newswire
May 14th, 2025
Neurocrine Biosciences Presents Findings Contributing To The Growing Body Of Evidence On The Impact Of High-Dose Glucocorticoids On Clinical Outcomes In Congenital Adrenal Hyperplasia

Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical OutcomesFindings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual MeetingSAN DIEGO, May 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including decreased bone mineral density, increased insulin resistance and higher body mass index, in patients with congenital adrenal hyperplasia. This study was presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Montreal, Canada.Congenital adrenal hyperplasia (CAH) is a rare, lifelong genetic condition linked to overproduction of adrenal androgens and cortisol deficiency. CAH is traditionally treated with lifelong high-dose glucocorticoids (GCs), which increase the risk of complications across multiple aspects of health. However, the relationship between GC dose and adverse clinical outcomes in CAH has not been fully explored. This systematic literature review was conducted to analyze the relationship between GC dose and clinical outcomes, and is the first to capture the impact of higher GC dose on the incidence and severity of all relevant adverse clinical outcomes in patients with CAH."CAH requires lifelong glucocorticoid therapy to manage adrenal androgen excess and cortisol deficiency, but high doses often lead to significant complications, including cardiometabolic, bone and growth issues," said Eiry W

Clinical Trial Vanguard
May 1st, 2025
Neurocrine Starts Phase 3 Trial of NBI-1117568 for Schizophrenia

Nxera Pharma's partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist, for schizophrenia treatment.